Main container

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Title
A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Code
AL-DES 01_RINGSIDE
Type
Sperimentale con farmaco
Start Year
2023
Status
In progress

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Clinical Trial
Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors
Read more